共 55 条
[2]
[5]
[7]
Odanacatib; a selective cathepsin K inhibitor to treat osteoporosis: safety; tolerability; pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers.[J].S. Aubrey Stoch;Stefan Zajic;Julie A. Stone;Deborah L. Miller;Lucas Bortel;Kenneth C. Lasseter;Barnali Pramanik;Caroline Cilissen;Qi Liu;Lida Liu;Boyd B. Scott;Deborah Panebianco;Yu Ding;Keith Gottesdiener;John A. Wagner.Br J Clin Pharmacol.2013, 5
[10]

